Search research articles
Contact Us
Filters
Showing results (61-70 of 70) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 70 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2017
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy
M Friedlander, J Rau, C K Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2021
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
K N Moore, A M Oza, N Colombo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 14, 2025
Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008
S Y Ryu, W Deng, K Albuquerque, et al.
Gynecologic Oncology
|
September 15, 2019
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer
I Vergote, A du Bois, A Floquet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study
B J Monk, M F Brady, C Aghajanian, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2024
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
B J Monk, M P Barretina-Ginesta, B Pothuri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2024
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial
M A Powell, L Bjørge, L Willmott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 20, 2025
Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study
R S Kristeleit, S Ghamande, A Lisyanskaya, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 11, 2025
Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses
J Mayadev, J C Vázquez Limón, F J Ramírez Godinez, et al.
Gynecologic Oncology
|
September 9, 2022
Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe
W L Van der Kolk, A G J Van der Zee, B M Slomovitz, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 70) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 70 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 22, 2017
Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy
M Friedlander, J Rau, C K Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2021
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
K N Moore, A M Oza, N Colombo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 14, 2025
Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008
S Y Ryu, W Deng, K Albuquerque, et al.
Gynecologic Oncology
|
September 15, 2019
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer
I Vergote, A du Bois, A Floquet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 2017
A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study
B J Monk, M F Brady, C Aghajanian, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2024
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
B J Monk, M P Barretina-Ginesta, B Pothuri, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2024
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial
M A Powell, L Bjørge, L Willmott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 20, 2025
Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study
R S Kristeleit, S Ghamande, A Lisyanskaya, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 11, 2025
Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses
J Mayadev, J C Vázquez Limón, F J Ramírez Godinez, et al.
Gynecologic Oncology
|
September 9, 2022
Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe
W L Van der Kolk, A G J Van der Zee, B M Slomovitz, et al.
Page
of 7